FDA inspection
The Gillette Company, LLC (subsidiary of Procter & Gamble): FDA inspection ending Sep 20, 2005
FDA inspection 396826 · Voluntary Action Indicated (VAI) · North Chicago, IL
Key facts
| Inspection ID | 396826 |
|---|---|
| Firm | The Gillette Company, LLC (subsidiary of Procter & Gamble) |
| FEI number | 1417171 |
| Address | 3500 16th St |
| City | North Chicago |
| State | IL |
| ZIP | 60064-1513 |
| Fiscal year | 2005 |
| Inspection end date | Sep 20, 2005 |
| Classification | Voluntary Action Indicated (VAI) |
| Project area | Colors and Cosmetics Technology|Colors and Cosmetics Technology|Colors and Cosmetics Technology|Colors and Cosmetics Technology|Colors and Cosmetics Technology|Colors and Cosmetics Technology|Colors and Cosmetics Technology|Colors and Cosmetics Technology|Colors and Cosmetics Technology|Colors and Cosmetics Technology|Colors and Cosmetics Technology|Colors and Cosmetics Technology|Colors and Cosmetics Technology|Colors and Cosmetics Technology|Colors and Cosmetics Technology|Colors and Cosmetics Technology|Colors and Cosmetics Technology|Colors and Cosmetics Technology|Colors and Cosmetics Technology|Colors and Cosmetics Technology|Colors and Cosmetics Technology|Colors and Cosmetics Technology|Colors and Cosmetics Technology|Colors and Cosmetics Technology|Colors and Cosmetics Technology|Colors and Cosmetics Technology|Colors and Cosmetics Technology|Colors and Cosmetics Technology|Colors and Cosmetics Technology|Colors and Cosmetics Technology|Colors and Cosmetics Technology|Colors and Cosmetics Technology|Colors and Cosmetics Technology|Colors and Cosmetics Technology|Colors and Cosmetics Technology|Colors and Cosmetics Technology|Colors and Cosmetics Technology|Colors and Cosmetics Technology|Colors and Cosmetics Technology|Colors and Cosmetics Technology|Colors and Cosmetics Technology|Colors and Cosmetics Technology|Colors and Cosmetics Technology|Colors and Cosmetics Technology|Colors and Cosmetics Technology|Colors and Cosmetics Technology|Colors and Cosmetics Technology|Colors and Cosmetics Technology|Colors and Cosmetics Technology|Colors and Cosmetics Technology|Colors and Cosmetics Technology|Colors and Cosmetics Technology|Colors and Cosmetics Technology|Colors and Cosmetics Technology|Colors and Cosmetics Technology|Colors and Cosmetics Technology|Colors and Cosmetics Technology|Colors and Cosmetics Technology|Colors and Cosmetics Technology|Colors and Cosmetics Technology|Colors and Cosmetics Technology|Colors and Cosmetics Technology|Colors and Cosmetics Technology|Colors and Cosmetics Technology|Colors and Cosmetics Technology|Colors and Cosmetics Technology|Colors and Cosmetics Technology|Colors and Cosmetics Technology|Colors and Cosmetics Technology|Colors and Cosmetics Technology|Colors and Cosmetics Technology|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance |
| Product type | Drugs, Food/Cosmetics |
At a glance
- None Citations
- 1–9 Posted citations
- No Warning letter followed
- Yes Form FDA 483 issued
- No Establishment inspection report (EIR) exists
- 1–9 Inspections at this FEI
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About FDA inspections
FDA inspections are classified as No Action Indicated (NAI), Voluntary Action Indicated (VAI) or Official Action Indicated (OAI). Inspections of individual clinical investigators are not published here.
Source: U.S. Food and Drug Administration (FDA), inspection classification data